These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

405 related articles for article (PubMed ID: 33990881)

  • 1. Pegfilgrastim for primary prophylaxis of febrile neutropenia in multiple myeloma.
    Cerchione C; Nappi D; Martinelli G
    Support Care Cancer; 2021 Nov; 29(11):6973-6980. PubMed ID: 33990881
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of two pegfilgrastim biosimilars: Tripegfilgrastim and pegteograstim.
    Kang KW; Lee BH; Jeon MJ; Yu ES; Kim DS; Lee SR; Sung HJ; Choi CW; Park Y; Kim BS
    Cancer Med; 2020 Sep; 9(17):6102-6110. PubMed ID: 32633471
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pegfilgrastim in primary prophylaxis of febrile neutropenia following frontline bendamustine plus rituximab treatment in patients with indolent non-Hodgkin lymphoma: a single center, real-life experience.
    Cerchione C; De Renzo A; Di Perna M; Della Pepa R; Pugliese N; Catalano L; Pane F; Picardi M
    Support Care Cancer; 2017 Mar; 25(3):839-845. PubMed ID: 27812763
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pegfilgrastim in primary prophylaxis of febrile neutropenia during chemotherapy of relapsed and refractory multiple myeloma: a real-life experience.
    Cerchione C; Catalano L; Pareto AE; Picardi M; Pane F
    Support Care Cancer; 2015 Feb; 23(2):301-2. PubMed ID: 25341551
    [No Abstract]   [Full Text] [Related]  

  • 5. Cost effectiveness of pegfilgrastim versus filgrastim after high-dose chemotherapy and autologous stem cell transplantation in patients with lymphoma and myeloma: an economic evaluation of the PALM Trial.
    Perrier L; Lefranc A; Pérol D; Quittet P; Schmidt-Tanguy A; Siani C; de Peretti C; Favier B; Biron P; Moreau P; Bay JO; Lissandre S; Jardin F; Espinouse D; Sebban C
    Appl Health Econ Health Policy; 2013 Apr; 11(2):129-38. PubMed ID: 23435861
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of effectiveness of biosimilar filgrastim (Nivestim™), reference Amgen filgrastim and pegfilgrastim in febrile neutropenia primary prevention in breast cancer patients treated with neo(adjuvant) TAC: a non-interventional cohort study.
    Brito M; Esteves S; André R; Isidoro M; Moreira A
    Support Care Cancer; 2016 Feb; 24(2):597-603. PubMed ID: 26111956
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of pegfilgrastim versus 6-day filgrastim primary prophylaxis in patients with non-Hodgkin's lymphoma receiving CHOP-21 in United States.
    Lyman G; Lalla A; Barron R; Dubois RW
    Curr Med Res Opin; 2009 Feb; 25(2):401-11. PubMed ID: 19192985
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effectiveness of biosimilar filgrastim vs. original granulocyte colony-stimulating factors in febrile neutropenia prevention in breast cancer patients.
    Puértolas I; Frutos Pérez-Surio A; Alcácera MA; Andrés R; Salvador MDT
    Eur J Clin Pharmacol; 2018 Mar; 74(3):315-321. PubMed ID: 29152672
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative effectiveness of colony-stimulating factors for febrile neutropenia: a retrospective study.
    Tan H; Tomic K; Hurley D; Daniel G; Barron R; Malin J
    Curr Med Res Opin; 2011 Jan; 27(1):79-86. PubMed ID: 21091127
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Febrile neutropenia hospitalization due to pegfilgrastim on-body injector failure compared to single-injection pegfilgrastim and daily injections with reference and biosimilar filgrastim: US cost simulation for lung cancer and non-Hodgkin lymphoma.
    McBride A; Krendyukov A; Mathieson N; Campbell K; Balu S; Natek M; MacDonald K; Abraham I
    J Med Econ; 2020 Jan; 23(1):28-36. PubMed ID: 31433700
    [No Abstract]   [Full Text] [Related]  

  • 11. Granulocyte colony-stimulating factors for febrile neutropenia prophylaxis following chemotherapy: systematic review and meta-analysis.
    Cooper KL; Madan J; Whyte S; Stevenson MD; Akehurst RL
    BMC Cancer; 2011 Sep; 11():404. PubMed ID: 21943360
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Granulocyte colony-stimulating factors used in clinical practice: PoloNord Registry-Based Cohort Italian Study.
    Fagnani D; Isa L; Verga MF; Nova P; Casartelli C; Filipazzi V; Danova M; Farina G; Pugliese P; Fava S; Bertolini A; Cimminiello C; Boracchi P; Marano G; Panzarino C;
    Tumori; 2014; 100(5):491-8. PubMed ID: 25343541
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pegfilgrastim and daily granulocyte colony-stimulating factor: patterns of use and neutropenia-related outcomes in cancer patients in Spain--results of the LEARN Study.
    Almenar D; Mayans J; Juan O; Bueno JM; Lopez JI; Frau A; Guinot M; Cerezuela P; Buscalla EG; Gasquet JA; Sanchez J
    Eur J Cancer Care (Engl); 2009 May; 18(3):280-6. PubMed ID: 19076208
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A single-arm, retrospective analysis of the incidence of febrile neutropenia using same-day versus next-day pegfilgrastim in patients with gastrointestinal cancers treated with FOLFOX or FOLFIRI.
    Eckstrom J; Bartels T; Abraham I; Patel H; Elquza E; Scott AJ; Malangone S; Hollings J; McBride A
    Support Care Cancer; 2019 Mar; 27(3):873-878. PubMed ID: 30090991
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A comparison of eflapegrastim to pegfilgrastim in the management of chemotherapy-induced neutropenia in patients with early-stage breast cancer undergoing cytotoxic chemotherapy (RECOVER): A Phase 3 study.
    Cobb PW; Moon YW; Mezei K; Láng I; Bhat G; Chawla S; Hasal SJ; Schwartzberg LS
    Cancer Med; 2020 Sep; 9(17):6234-6243. PubMed ID: 32687266
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness of filgrastim and pegfilgrastim as primary prophylaxis against febrile neutropenia in lymphoma patients.
    Lathia N; Isogai PK; De Angelis C; Smith TJ; Cheung M; Mittmann N; Hoch JS; Walker S
    J Natl Cancer Inst; 2013 Aug; 105(15):1078-85. PubMed ID: 23873405
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative effectiveness of granulocyte colony-stimulating factors to prevent febrile neutropenia and related complications in cancer patients in clinical practice: A systematic review.
    Mitchell S; Li X; Woods M; Garcia J; Hebard-Massey K; Barron R; Samuel M
    J Oncol Pharm Pract; 2016 Oct; 22(5):702-16. PubMed ID: 26769697
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design Rationale and Development Approach for Pegfilgrastim as a Long-Acting Granulocyte Colony-Stimulating Factor.
    Arvedson T; O'Kelly J; Yang BB
    BioDrugs; 2015 Jun; 29(3):185-98. PubMed ID: 25998211
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy, effectiveness and safety of long-acting granulocyte colony-stimulating factors for prophylaxis of chemotherapy-induced neutropenia in patients with cancer: a systematic review.
    Pfeil AM; Allcott K; Pettengell R; von Minckwitz G; Schwenkglenks M; Szabo Z
    Support Care Cancer; 2015 Feb; 23(2):525-45. PubMed ID: 25284721
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Overuse and underuse of pegfilgrastim for primary prophylaxis of febrile neutropenia.
    Zullo AR; Lou U; Cabral SE; Huynh J; Berard-Collins CM
    J Oncol Pharm Pract; 2019 Sep; 25(6):1357-1365. PubMed ID: 30124123
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.